ABVX.PA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:35):

Stats
今日成交量	13 478.00
平均成交量	30 185.00
市值	932.44M
EPS	€0 ( 2024-04-07 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-4.32
ATR14	€0.0470 (0.32%)

音量相关性

長: -0.05 (neutral)

短: 0.77 (moderate)

Signal:(59.777) Neutral

Abivax SA 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Abivax SA 相关性 - 货币/商品

-0.16
( neutral )

-0.25
( neutral )

0.00
( neutral )

0.01
( neutral )

0.09
( neutral )

-0.16
( neutral )

Abivax SA 财务报表

Annual	2023
营收:	€4.62M
毛利润:	€3.91M (84.70 %)
EPS:	€-3.43

FY	2023
营收:	€4.62M
毛利润:	€3.91M (84.70 %)
EPS:	€-3.43

FY	2022
营收:	€0
毛利润:	€-71 000.00 (0.00 %)
EPS:	€-3.13

FY	2021
营收:	€37 000.00
毛利润:	€37 000.00 (100.00 %)
EPS:	€-3.39

Financial Reports:

No articles found.

Abivax SA

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.